Recce Pharmaceuticals Ltd. (AU:RCE)
ASX:RCE
Want to see AU:RCE full AI Analyst Report?
Top Page
Recce Pharmaceuticals Ltd.
(Sydney:RCE)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.49
▲(18.78% Upside)
Action:Reiterated
Date:03/04/26
The score is pressured primarily by poor financial performance (declining revenue, severe losses, and negative equity). Technical indicators also point to strong bearish momentum, while valuation offers limited support due to negative earnings and no dividend yield provided.
Positive Factors
Free cash flow growth
A 51.97% free cash flow growth rate indicates improving cash generation versus prior periods. Over a 2-6 month horizon this strengthens runway for clinical programs, reduces near-term dilution needs, and provides more financial flexibility to fund R&D or regulatory activities.
Negative Factors
Revenue decline
A 21.73% decline in revenue signals weakening top-line momentum, reducing internal funding capacity for costly clinical and regulatory programs. Over months this increases dependence on external capital, pressures operating plans, and limits ability to scale or commercialize without further financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Free cash flow growth
A 51.97% free cash flow growth rate indicates improving cash generation versus prior periods. Over a 2-6 month horizon this strengthens runway for clinical programs, reduces near-term dilution needs, and provides more financial flexibility to fund R&D or regulatory activities.
Read all positive factors
Recce Pharmaceuticals Ltd. (RCE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$138.81M
Dividend YieldN/A
Average Volume (3M)154.69K
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue GrowthN/A
EPS Growth-37.23%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.12
Shares Outstanding289,183,400
10 Day Avg. Volume112,630
30 Day Avg. Volume154,688
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)-22.52
Price to Sales (P/S)9.15
P/FCF Ratio-3.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)AU$4.25M
Recce Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's...
How the Company Makes Money
null...
Recce Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
30
Negative
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 562.52K | 7.51M | 5.03M | 4.37M | 3.08M | 1.64M |
| Gross Profit | -1.56M | -2.94M | -2.19M | 4.15M | 2.90M | 1.34M |
| EBITDA | -26.98M | -20.33M | -21.35M | -16.99M | -13.87M | -14.77M |
| Net Income | -30.25M | -21.43M | -17.66M | -13.08M | -10.99M | -13.51M |
Balance Sheet | ||||||
| Total Assets | 2.04M | 12.41M | 6.37M | 2.56M | 12.62M | 21.68M |
| Cash, Cash Equivalents and Short-Term Investments | 602.99K | 10.45M | 4.42M | 1.56M | 11.58M | 20.87M |
| Total Debt | 11.26M | 10.77M | 811.19K | 250.57K | 74.76K | 126.95K |
| Total Liabilities | 20.66M | 15.47M | 15.89M | 5.14M | 2.56M | 1.18M |
| Stockholders Equity | -18.62M | -3.05M | -9.52M | -2.59M | 10.06M | 20.50M |
Cash Flow | ||||||
| Free Cash Flow | -23.79M | -20.47M | -13.15M | -12.73M | -9.05M | -7.93M |
| Operating Cash Flow | -23.75M | -20.44M | -13.01M | -12.69M | -9.01M | -7.86M |
| Investing Cash Flow | 115.85K | -443.90K | -141.90K | -38.63K | -40.34K | -76.01K |
| Financing Cash Flow | 22.06M | 26.92M | 16.00M | 2.71M | -240.50K | 26.12M |
Recce Pharmaceuticals Ltd. Technical Analysis
Negative
0.41
Price Trends
0.51
Negative
0.52
Negative
0.51
Negative
Market Momentum
>-0.01
Positive
41.71
Neutral
19.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RCE, the sentiment is Negative. The current price of 0.41 is below the 20-day moving average (MA) of 0.52, below the 50-day MA of 0.51, and below the 200-day MA of 0.51, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.71 is Neutral, neither overbought nor oversold. The STOCH value of 19.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:RCE.
Recce Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$71.50M | -7.81 | -62.49% | ― | ― | -13.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$85.82M | -10.86 | -40.65% | ― | -100.00% | -11.11% | |
43 Neutral | AU$59.03M | -7.66 | -18.71% | ― | ― | 21.23% | |
41 Neutral | AU$138.81M | -4.64 | 279.21% | ― | ― | -37.23% | |
41 Neutral | AU$47.82M | -0.50 | -134.65% | ― | ― | 62.72% | |
39 Underperform | AU$130.51M | -8.16 | -30.19% | ― | ― | 62.66% |
* Healthcare Sector Average
AU:RCE
Recce Pharmaceuticals Ltd.
0.48
0.19
62.71%
AU:ATX
Amplia Therapeutics
0.12
-0.06
-36.11%
AU:IMU
Imugene
0.12
-0.33
-73.98%
AU:ATH
Alterity Therapeutics
0.60
0.10
20.00%
AU:PTX
Prescient Therapeutics Limited
0.07
0.02
44.68%
AU:ALA
Arovella Therapeutics Limited
0.07
-0.02
-21.11%
Recce Pharmaceuticals Ltd. Corporate Events
Recce Clarifies Middle East Licensing Term Sheet and Highlights Partner Strength
May 27, 2026
Recce Pharmaceuticals has issued an addendum to its announcement of a non-binding 10-year exclusive licensing term sheet with a major publicly listed Middle Eastern pharmaceutical company. The addendum clarifies that Recce does not view revealing ...
Recce Strikes 10-Year MENA Licensing Deal for Diabetic Foot Infection Gel
May 27, 2026
Recce Pharmaceuticals has signed a non-binding term sheet with a major publicly listed Middle Eastern drugmaker for a 10-year exclusive licence to register, market and distribute its R327 Topical Gel for diabetic foot infections across Saudi Arabi...
Recce deepens U.S. Army ties and expands global patent reach in Q3 FY2026
Apr 30, 2026
Recce Pharmaceuticals reported its Q3 FY2026 highlights, positioning itself as a specialist in next-generation synthetic anti-infectives with expanding global intellectual property and clinical programs. The company secured a AUD 5.3 million RD ta...
Recce Clears Key Indonesian Inspection Milestone in Phase 3 Diabetic Foot Trial
Apr 21, 2026
Recce Pharmaceuticals has reported a positive outcome from a routine regulatory inspection by Indonesia’s National Agency of Drug and Food Control of one of its Phase 3 clinical trial sites for diabetic foot infections. The inspection found ...
Recce Pharmaceuticals Options Lapse Trims Potential Share Dilution
Apr 15, 2026
Recce Pharmaceuticals has notified the market of the cessation of 66,667 RCEAO options, which were due to expire on 7 November 2029 with an exercise price of $0.56. The options have lapsed because the conditional rights attached to them were not s...
Recce Wins Brazilian Patent for Broad-Spectrum Anti-Infective Portfolio
Mar 24, 2026
Recce Pharmaceuticals has secured a key Brazilian patent for its RECCE 327 and RECCE 529 anti-infective compounds, extending protection to 2041 and covering their preparation, broad therapeutic use against multiple infections, and diverse delivery...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.